相关实验视频

Updated: Jul 9, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

同时EGFR突变和ALK重组在肺腺癌治疗用奥西默提尼布治疗

David Thomas¹, McKenzie E Maloney¹, Girindra Raval¹

¹Hematology and Oncology, Medical College of Georgia, Augusta University, Augusta, USA.

|December 4, 2023

概括

本案例系列探讨了罕见的肺癌与共存的表皮生长因子受体 (EGFR) 突变和形淋巴瘤激酶 (ALK) 重组的罕见病例. 在这些具有挑战性的病例中,用EGFR-氨酸激酶抑制剂 (TKIs) 治疗显示出混合反应.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

肺癌仍然是美国癌症死亡的主要原因,目标治疗显著改善了生存率.
皮表皮生长因子受体 (EGFR) 突变和形淋巴瘤激酶 (ALK) 重组是非小细胞肺癌的关键驱动因素.
EGFR突变和ALK重组的同时发生是罕见的,这带来了独特的治疗挑战.

研究的目的:

描述两个IV期肺腺癌的病例,同时存在EGFR突变和ALK重组.
调查这些罕见的遗传共发生的临床相关性和治疗结果.

主要方法:

一系列病例描述了两个患有IV期腺癌的患者.
分子研究以确定EGFR突变 (L861Q,L858R) 和ALK基因融合.
用玛刀放射手术和EGFR-氨酸激酶抑制剂 (TKI), osimertinib 的治疗.

主要成果:

案例1:73岁的男性患有动脉;EGFR L861Q突变和ALK融合. 用osimertinib治疗,经历了疾病进展,并去世.
案例2:64岁女性呼吸障碍;EGFR L858R突变和ALK融合. 用osimertinib治疗,显示大脑转移的显著减少.

结论:

同时存在的EGFR突变和ALK重组在肺癌中是罕见的,并提出治疗挑战.
在这两种情况下,EGFR-TKI治疗显示出混合反应.
需要进行进一步的研究,以为这种特定患者群体建立最佳的治疗策略.

关键词:

基突变是一种基突变.在 EGFR 突变中.肺癌是一种肺癌.奥西米尔丁尼布 (osimertinib) 是一种治疗治疗治疗治疗治疗治疗

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...